UOC
CDTX

UBS O'Connor’s Cidara Therapeutics CDTX Stock Holding History

UBS O'Connor’s Portfolio CDTX Stock Details CDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$69.7M Buy
+315,474
New +$51M 1.86% 14
2016
Q2 		– Sell
-1,962
Closed -$498K – 416
2016
Q1 		$498K Sell
1,962
-38
-2% -$8.76K 0.01% 392
2015
Q4 		$686K Sell
2,000
-1,311
-40% -$394K 0.01% 378
2015
Q3 		$842K Hold
3,311
– – 0.01% 444
2015
Q2 		$928K Buy
+3,311
New +$1.02M 0.01% 602

Other funds holding CDTX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JFG
Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

UBS O'Connor's CDTX Position: Q4 2025 in Review

UBS O'Connor opened a new position in Cidara Therapeutics (CDTX) in Q4 2025: 315,474 shares worth $69.7M. The stake represents 1.86% of the portfolio and ranks #14 among its holdings. This is a return to the name: UBS O'Connor previously reported a position in CDTX as recently as Q1 2016.

UBS O'Connor first reported a position in CDTX in Q2 2015 and has held it in 5 quarters since. 255 funds tracked by Wall St. Rank hold CDTX as of Q4 2025.

  • UBS O'Connor held 315,474 shares of Cidara Therapeutics worth $69.7M as of Q4 2025.
  • Cidara Therapeutics was a new UBS O'Connor position in Q4 2025.
  • Cidara Therapeutics made up 1.86% of UBS O'Connor's portfolio in Q4 2025, its #14 holding.
  • UBS O'Connor first reported a position in Cidara Therapeutics in Q2 2015 and has held it in 5 quarters since.
  • 255 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q4 2025.

Based on UBS O'Connor's 13F filing for Q4 2025, filed 13 Feb 2026.